Results from a phase III trial, presented at the virtual annual congress of the European Society for Medical Oncology and simultaneously published in Lancet Oncology, revealed that 5 years of extended treatment with aromatase inhibitor letrozole led to a significant improvement in disease-free survival (DFS) when compared with standard duration of 2 to 3 years among postmenopausal breast cancer patients who had already been given tamoxifen for 2 to 3 years.

DFS events were noted in 20.7% of patients in the extended group and 25.4% of patients in the control group following a median follow-up of 11.7 years. The 12-year rates of DFS were 67% and 62%, respectively… (Medpage Today)